Karyopharm CFO awarded 32,415 RSUs

Karyopharm Therapeutics Inc. reported an equity compensation award to its EVP, CFO & Treasurer, Lori Macomber.

Rhea-AI Filing Summary

Karyopharm Therapeutics Inc. reported an equity compensation award to its EVP, CFO & Treasurer, Lori Macomber. She received 32,415 restricted stock units (RSUs) of Karyopharm common stock at a grant price of $0.

The RSUs convert into common stock on a one-for-one basis. They vest in two equal installments, with 50% vesting on January 31, 2027 and the remaining 50% on January 31, 2028. Following this grant, Macomber beneficially owns 86,731 shares of Karyopharm common stock.

Insider Trade Summary

Grant/Award: 32,415 shares

Grant/Award 1 txn

Insider Macomber Lori

Role EVP, CFO & Treasurer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	32,415	$0.00	$0.00

Holdings After Transaction: Common Stock — 86,731 shares (Direct)

Footnotes (1)

1. F1. Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 50% of the shares on January 31, 2027, with the remaining 50% vesting on January 31, 2028.

FAQ

What insider transaction did Karyopharm (KPTI) report for Lori Macomber?

Karyopharm reported an equity award to EVP, CFO & Treasurer Lori Macomber of 32,415 restricted stock units (RSUs). These RSUs are a form of stock-based compensation and will convert into common stock over time as they vest under the company’s equity plan.

How many KPTI shares does Lori Macomber beneficially own after this Form 4?

After the reported grant, EVP, CFO & Treasurer Lori Macomber beneficially owns 86,731 shares of Karyopharm Therapeutics common stock. This total reflects the newly awarded 32,415 RSUs in addition to her previously held shares, as disclosed in the Form 4 filing.

What are the vesting terms of Lori Macomber’s 32,415 KPTI RSUs?

The 32,415 RSUs awarded to Lori Macomber vest in two equal tranches. 50% of the RSUs vest on January 31, 2027, and the remaining 50% vest on January 31, 2028, subject to the conditions of Karyopharm’s 2022 Equity Incentive Plan.

What is the exercise or purchase price of Lori Macomber’s KPTI RSU grant?

The Form 4 states a price of $0 for the 32,415 RSUs granted to Lori Macomber. RSUs typically do not require a cash exercise; instead, they convert into common stock on a one-for-one basis when the vesting conditions are satisfied.

Under which plan were Lori Macomber’s KPTI RSUs granted?

The 32,415 RSUs granted to Lori Macomber were issued under the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. This plan provides for stock-based awards that align executive compensation with shareholder interests through equity ownership.

What does one-for-one RSU conversion mean for KPTI shareholders?

The filing notes these RSUs convert into Karyopharm common stock on a one-for-one basis. This means each RSU becomes one share of common stock upon vesting, directly linking the value of the award to the company’s share price performance over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/03/2026 - 04:29 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Macomber Lori

(Last) (First) (Middle)

C/O KARYOPHARM THERAPEUTICS INC.

85 WELLS AVENUE

(Street)

NEWTON MA 02459

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Karyopharm Therapeutics Inc. [ KPTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CFO & Treasurer

3. Date of Earliest Transaction (Month/Day/Year)
01/31/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/31/2026		A		32,415(1)	A	$0	86,731	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 50% of the shares on January 31, 2027, with the remaining 50% vesting on January 31, 2028.

	/s/ Nancy Smith as Attorney-in-Fact for Lori Macomber	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.